[18F]FES PET/.CT in Uterine Cancer

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Jun 21, 2023

Keywords

ClinConnect Summary

**Summary of the Clinical Trial: [18F]FES PET/CT in Uterine Cancer**

This clinical trial is looking at a special imaging technique called [18F]fluoroestradiol (FES) PET/CT to help understand how estrogen receptors are working in women with recurrent or metastatic uterine cancer. The study aims to see if this imaging can provide valuable information about the cancer before starting a new treatment. Women who are at least 18 years old and have been diagnosed with recurrent or metastatic uterine cancer may be eligible to participate. This includes those with cancer that hasn't been surgically removed and who have evidence of the disease from standard imaging tests.

If you join this trial, you will have an FES PET/CT scan to assess the activity of your cancer before beginning a new treatment. Some participants may have a second scan later, especially if there are signs that the cancer may be progressing. Importantly, the results of these scans will be shared with your doctor but will not directly influence treatment decisions. The trial is currently recruiting participants, and you should discuss with your healthcare provider if you meet the criteria and if this study might be a good option for you.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria
• • 1. Participants will be ≥ 18 years of age
• • 2. Recurrent or metastatic or intact non-operated uterine cancer not treated with surgery that is biopsy-proven or demonstrated on other standard of care imaging (e.g. CT, FDG PET/CT, MRI, bone scan, x-ray, ultrasound)
• • 3. At least one lesion outside the liver detected by standard of care imaging (e.g.CT, FDG PET/CT, MRI, bone scan, x-ray, ultrasound)
• • 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• • 5. Subjects that are currently on or have recently discontinued tamoxifen or fulvestrant would require an 8-week or 28-week, respectively, washout period prior to FES PET/CT scan.
• • Exclusion Criteria
• • 1. Females who report they are pregnant at screening will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential prior to FES injection.
• • 2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• • 3. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study